دورية أكاديمية
Diagnostic probability classification in suspected borreliosis by a novel Borrelia C6-peptide IgG1- subclass antibody test.
| العنوان: | Diagnostic probability classification in suspected borreliosis by a novel Borrelia C6-peptide IgG1- subclass antibody test. |
|---|---|
| المؤلفون: | Nyman D; The Åland Group for Borreliosis Research, Mariehamn, Finland.; Bimelix Laboratory, Mariehamn, Finland., Nordberg M; The Åland Group for Borreliosis Research, Mariehamn, Finland.; Department of Infection, Åland Public Health Care Services, Mariehamn, Finland., Nyberg C; The Åland Group for Borreliosis Research, Mariehamn, Finland.; Department of Infection, Åland Public Health Care Services, Mariehamn, Finland., Olausson S; The Åland Group for Borreliosis Research, Mariehamn, Finland.; Bimelix Laboratory, Mariehamn, Finland., Carlströmer Berthen N; The Åland Group for Borreliosis Research, Mariehamn, Finland.; Bimelix Laboratory, Mariehamn, Finland., Carlsson SA; The Åland Group for Borreliosis Research, Mariehamn, Finland.; Bimelix Laboratory, Mariehamn, Finland. |
| المصدر: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2023 Sep 11; Vol. 13, pp. 1108115. Date of Electronic Publication: 2023 Sep 11 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media SA |
| مواضيع طبية MeSH: | Borrelia* , Borrelia burgdorferi Group* , Lyme Disease* , Borrelia burgdorferi*, Humans ; Retrospective Studies ; Immunoglobulin G ; Peptides ; Probability ; Antibodies, Bacterial |
| مستخلص: | The tick-borne multisystemic infection caused by Borrelia burgdorferi sensu lato , Lyme borreliosis, or Lyme disease, occurring in temperate regions of the northern hemisphere, continues to spread geographically with the expanding tick population. Despite the rising perceived risk of infection in the population, the clinical diagnosis of Borrelia infection is not always obvious and the most important laboratory test, antibody detection, has limited accuracy in diagnosing active disease. According to international guidelines, the primary serology test, which has a high sensitivity-low specificity, should, be verified using a high specificity confirmation test to improve the specificity. However, this enhancement in specificity comes at the cost of lower sensitivity. This two-step procedure is often omitted in everyday clinical practice. An optimal primary test would be one where no secondary tests for confirmation would be necessary. In the present study, the performance of a novel assay for quantitating IgG1-subclass antibodies to Borrelia C6-peptide was compared to a commercial reference assay of total IgG and IgM antibodies to Borrelia C6-peptide in the setting of a high endemic area for borreliosis. A derivation study on a retrospective clinical material was performed to compare the performance parameters and assess the discriminatory properties of the assays, followed by a prospective validation study. The IgG1-antibody assay achieved comparable summary performance parameters to those of the reference assay. The sensitivity was almost 100% while the specificity was about 50%. In a high-endemic setting, characterized by high background seropositivity of about 50% and disease prevalence of approximately 10%, antibody tests are unable to rule-in active Borrelia infection. The rule-out assessment of the methods revealed that of 1000 patients, 7 - 54 with negative results based on the reference method could have an active Borrelia infection. Such uncertainty was not found for the index test and may help improve the risk classification of patients. Competing Interests: DN, SO, and S-AC are partners in the Bimelix Laboratory. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Nyman, Nordberg, Nyberg, Olausson, Carlströmer Berthen and Carlsson.) |
| References: | Clin Microbiol Infect. 2018 Dec;24(12):1234-1240. (PMID: 29674128) Clin Vaccine Immunol. 2007 Aug;14(8):931-6. (PMID: 17567769) Evid Based Med. 2013 Feb;18(1):5-10. (PMID: 22740357) J Clin Invest. 2004 Apr;113(8):1093-101. (PMID: 15085185) Clin Infect Dis. 2001 Sep 15;33(6):780-5. (PMID: 11512082) J Med Microbiol. 1994 Apr;40(4):293-302. (PMID: 8151682) Clin Infect Dis. 2020 Dec 15;71(12):3125-3127. (PMID: 31995636) Infect Immun. 1999 Dec;67(12):6702-6. (PMID: 10569796) Ann Intern Med. 1997 Dec 15;127(12):1109-23. (PMID: 9412316) Microorganisms. 2022 Mar 12;10(3):. (PMID: 35336182) Lancet Reg Health Eur. 2021 May 27;6:100142. (PMID: 34557833) Clin Microbiol Infect. 2005 Feb;11(2):147-50. (PMID: 15679490) Infect Immun. 2000 Apr;68(4):2349-52. (PMID: 10722641) Clin Biochem Rev. 2008 Aug;29 Suppl 1:S49-52. (PMID: 18852857) Clin Chem. 1991 Jul;37(7):1153-60. (PMID: 1855284) Clin Infect Dis. 2020 Dec 15;71(12):3118-3124. (PMID: 31996890) Clin Exp Immunol. 1987 Sep;69(3):618-23. (PMID: 3665187) BMC Infect Dis. 2016 Mar 25;16:140. (PMID: 27013465) N Engl J Med. 2001 Jul 12;345(2):115-25. (PMID: 11450660) Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1933-1945. (PMID: 31399914) Vector Borne Zoonotic Dis. 2003 Winter;3(4):215-27. (PMID: 14733674) J Clin Microbiol. 1990 Mar;28(3):637-8. (PMID: 2182679) Clin Microbiol Rev. 2021 Jan 27;34(2):. (PMID: 33504503) Ticks Tick Borne Dis. 2016 Feb;7(1):71-79. (PMID: 26341726) Neurology. 1991 Oct;41(10):1571-82. (PMID: 1922798) FEMS Microbiol Rev. 2018 May 1;42(3):233-258. (PMID: 29893904) Clin Microbiol Infect. 2006 May;12(5):496-7. (PMID: 16643532) J Clin Microbiol. 1999 Dec;37(12):3990-6. (PMID: 10565920) J Clin Invest. 2020 May 1;130(5):2148-2151. (PMID: 32281948) Lancet. 2003 Nov 15;362(9396):1639-47. (PMID: 14630446) Nat Rev Dis Primers. 2016 Dec 15;2:16090. (PMID: 27976670) Eur J Clin Microbiol Infect Dis. 1999 Sep;18(9):621-9. (PMID: 10534183) FEMS Immunol Med Microbiol. 2007 Feb;49(1):13-21. (PMID: 17266710) BMC Infect Dis. 2022 Sep 28;22(1):756. (PMID: 36171561) |
| فهرسة مساهمة: | Keywords: Borrelia infection; C6-peptide; IgG1-antibody; diagnostics; probability; serology |
| المشرفين على المادة: | 0 (Immunoglobulin G) 0 (Peptides) 0 (Antibodies, Bacterial) |
| تواريخ الأحداث: | Date Created: 20230927 Date Completed: 20231023 Latest Revision: 20231023 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10518385 |
| DOI: | 10.3389/fcimb.2023.1108115 |
| PMID: | 37753485 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2235-2988 |
|---|---|
| DOI: | 10.3389/fcimb.2023.1108115 |